TAS-102 Provides Survival Benefit in Refractory Colorectal Cancer

Share this content:

the Cancer Therapy Advisor take:

In patients with refractory colorectal cancer, TAS-102 was associated with a significant improvement in overall survival compared with placebo, a study published in the New England Journal of Medicine has shown.

For the double-blind study, researchers enrolled 800 patients with refractory colorectal cancer and randomly assigned them 2:1 to receive TAS-102 or placebo.

Results showed that the median overall survival was 5.3 months and 7.1 months in the placebo and TAS-102 groups, respectively (HR for death = 0.68; 95% CI: 0.58-0.81; P < 0.001).

In regard to safety, the most common adverse events associated with TAS-102 were neutropenia, leukopenia, and febrile neutropenia. One patient died as a result of TAS-102 treatment. Median time to worsening performance status was also 1.7 months longer in the TAS-102 arm than the placebo arm (HR = 0.66; 95% CI: 0.56-0.78; P < 0.001).

TAS-102 is an oral agent that combines trifluridine and tipiracil hydrochloride. Previous studies conducted mostly in Japan that it was effective in the treatment of patients with refractory colorectal cancer.

The FDA has approved a label update for Zytiga (abiraterone acetate) plus prednisone based on final
In patients with refractory colorectal cancer, TAS-102 was associated with a significant improvement in overall survival.
We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients.
READ FULL ARTICLE From New England Journal of Medicine

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters